title: Is tranexamic acid safe in patients undergoing coronary endarterectomy?
abstract: BACKGROUND
  Patients undergoing coronary endarterectomy during coronary artery bypass grafting (CABG) are at increased risk of perioperative myocardial infarction due to coronary intimal disruption. Data assessing the safety of the antifibrinolytic drug tranexamic acid (TA) in patients undergoing this procedure are lacking.
  
  
  METHODS
  From September 1997 to December 1999, 221 patients underwent nonemergency primary CABG with endarterectomy of the right coronary artery alone in 149, the left anterior descending in 35, or both right and left anterior descending in 27. TA was administered intraoperatively to 87 patients (TA group: average total dose 62 +/- 4.4 mg/kg; range 20 to 109 mg/kg), and was not administered to 134 patients (No TA group).
  
  
  RESULTS
  The patient characteristics of the 2 groups were similar. In-hospital mortality consisted of 2 patients in the TA group and 4 patients in the No TA group. Perioperative myocardial infarction rates were 2% and 5% in the TA and No TA groups, respectively (p = 0.49). The relative risk for any type of perioperative cardiac ischemic event in the TA group versus the No TA group was 0.77 (95% CI; 0.4, 1.2). Patients in the TA group had a significant reduction in postoperative chest tube drainage (685 versus 894 mL in the TA versus No TA groups, respectively) and in the use of fresh-frozen plasma (p = 0.03).
  
  
  CONCLUSIONS
  These results suggest that the clinical effectiveness of tranexamic acid in reducing postoperative blood loss in patients undergoing coronary endarterectomy is not associated with a higher incidence of myocardial ischemia-related complications.
authors.affiliation: Department of Surgery and Anesthesia, University of Ottawa Heart Institute, Ontario, Canada.
authors.forename: M A
authors.initials: MA
authors.lastname: Ruel
authors.forename: F
authors.initials: F
authors.lastname: Wang
authors.forename: M E
authors.initials: ME
authors.lastname: Bourke
authors.forename: J Y
authors.initials: JY
authors.lastname: Dupuis
authors.forename: J A
authors.initials: JA
authors.lastname: Robblee
authors.forename: W J
authors.initials: WJ
authors.lastname: Keon
authors.forename: F D
authors.initials: FD
authors.lastname: Rubens
mesh_terms: D000368:Aged; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000401:mortality / Q000601:surgery*; D004691:Endarterectomy; D005260:Female; D006083:Graft Occlusion, Vascular / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000401:mortality / Q000517:prevention & control; D011183:Postoperative Complications / Q000139:chemically induced* / Q000401:mortality / Q000517:prevention & control; D012189:Retrospective Studies; D012306:Risk; D015996:Survival Rate; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D014148:Tranexamic Acid